Newsfeeds - Spark Newswire

1 minute read

Zentalis Pharmaceuticals Q2 EPS $1.34 Up From $(0.78) YoY

Today, 3:05 PM

Zentalis Pharmaceuticals (NASDAQ:ZNTL) reported quarterly earnings of $1.34 per share. This is a 271.79 percent increase over losses of $(0.78) per share from the same period last year.

ZNTL

5 minute read

The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout

By Shanthi Rexaline

Today, 3:05 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 28)

ABUS

1 minute read

Zentalis Secures $150M In Equity Funding

By Vandana Singh

Today, 3:05 PM

Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) priced an underwritten public offering of 3.1 million shares at $48.50 per share, for gross proceeds of…

ZNTL

2 minute read

Movers

12 Health Care Stocks Moving In Monday’s After-Market Session

By Benzinga Insights

Today, 3:05 PM

Gainers SCWorx (NASDAQ:WORX) shares rose 8.38% to $1.81 during Monday's after-market session. SCWorx's trading volume hit 504.7K shares by close, accounting for 148.37% of its average volume over the last 100 days. The market value of their outstanding shares is at $18.1 million.

AGRX

1 minute read

News

Zentalis Pharmaceuticals Announces Updates Across Its Pipeline Including Promising New Interim Clinical Data On ZN-c3 And ZN-c5 And Two Potentially Registrational Trials For ZN-c3, With The First Trial Already Initiated

By Benzinga Newsdesk

Today, 3:05 PM

Reports additional ZN-c3 Phase 1 interim monotherapy data, demonstrating increased tumor reduction and durability in the exceptional responder population, as well as newly confirmed responses and an additional

ZNTL

Latest news

Zentalis Pharmaceuticals Q2 EPS $1.34 Up From $(0.78) YoY

The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout

Zentalis Secures $150M In Equity Funding

12 Health Care Stocks Moving In Monday’s After-Market Session

Zentalis Pharmaceuticals Announces Updates Across Its Pipeline Including Promising New Interim Clinical Data On ZN-c3 And ZN-c5 And Two Potentially Registrational Trials For ZN-c3, With The First Trial Already Initiated